Yarrow Bioscience

Yarrow Bioscience Goodwill/Assets

Goodwill to Total Assets Ratio of Yarrow Bioscience (YARW) as of Oct 17, 2026.

Goodwill/Assets

-

Last updated:

Goodwill to Total Assets Ratio of Yarrow Bioscience is 2026 - . Goodwill to Total Assets Ratio of Yarrow Bioscience was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Yarrow Bioscience Stock analysis

What does Yarrow Bioscience do? Yarrow Bioscience Inc, based in New York, is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. Its lead candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for treating Graves' disease and thyroid eye disease. Listed on 25 January 2018, the company operates with a team of 10 employees. Yarrow Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Yarrow Bioscience stock

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio Yarrow Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's Yarrow Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Yarrow Bioscience

All Key Metrics — Yarrow Bioscience